Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01713738 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
A Phase 1 study, sponsored by Neufeld, Ellis J, MD, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01713738 is a Phase 1 study that has completed, run by Neufeld, Ellis J, MD, PhD. The registered enrollment target is 36 participants.
The verdict
NCT01713738, a Phase 1 study, has completed, sponsored by Neufeld, Ellis J, MD, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of rituximab in children ages 18 months to 18 years, who have severe, chronic ITP. Eligible patients with either primary or secondary ITP are treated with rituximab once a week for 4 doses, and then followed for up to one year. Response is defined as having a platelet count greater than or equal to 50,000/mL on four consecutive weekly measures beginning anytime in weeks 9 - 12.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01713738
The ClinicalTrials.gov registry entry for NCT01713738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neufeld, Ellis J, MD, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT01713738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01713738 about?
NCT01713738 is a clinical study titled "Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)". The purpose of the study is to evaluate the safety and efficacy of rituximab in children ages 18 months to 18 years, who have severe, chronic ITP. Eligible patients with either primary or secondary ITP are treated with rituximab once a week for 4 doses, and then followed for up to one year. Response...
What is the current status of trial NCT01713738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2003-05. Estimated completion is 2005-12.
What interventions are being tested in trial NCT01713738?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT01713738?
This trial is sponsored by Neufeld, Ellis J, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.